13 June 2008
SOLVO introducing B-CLEAR® technology
SOLVO is the exclusive commercial provider of B-CLEAR® kits and a provider of B-CLEAR® services in Europe.
Qualyst, Inc.'s patented B-CLEAR® sandwich-cultured hepatocyte technology is the only in vitro method which can evaluate a compound's hepatobiliary disposition, predict in vivo hepatic uptake and biliary clearance, and assess drug transporter-based inhibition. B-CLEAR® technology can be used by pharmaceutical and biotechnology companies to differentiate and select leads and candidates, predict dose and pharmacokinetic or toxicologic interspecies differences, and identify potential drug-drug interactions.
Research using B-CLEAR® can address critical questions such as:- What is the extent of a compound's hepatic uptake and biliary excretion?
- What is the potential for in vivo biliary clearance (rat and human)?
- Are there interspecies differences in the hepatic uptake and biliary clearance of a compound and/or its metabolites?
- Which drug candidates have optimal transport properties?
- What transporters are involved in the hepatobiliary disposition of the compounds and their metabolites?
In vitro single transporter-drug interaction studies are conducted on SOLVO cell and membrane vesicles based systems. - What is the potential for drug-drug interactions at the level of hepatobiliary transport?
The B-CLEAR® technology can also be used to predict the potential of drugs to interact with the elimination of endogenous substrates (e.g., bilirubin, taurocholate) which may result in hepatotoxicity (cholestasis, jaundice) in vivo.
A
B
Effect of indomethacin (100 mM) on efflux of 5,(6)-carboxy-2',7'-dichlorofluorescein (CDCF) into bile canaliculi in sandwich-cultured rat hepatocytes visualized by confocal laser microscopy (A), and measured spectrofluorimetrically (B).
The following B-CLEAR® products and services are available from SOLVO in Europe:
B-CLEAR® Kits:- B-CLEAR® -RT (Rat) Kit
- B-CLEAR® -HU (Human) Kit - under development
Rat
- Mrp2 efflux inhibition with Estradiol-17-beta-glucuronide as probe substrate
- Mrp2 efflux inhibition with Bilirubin glucuronide as probe substrate
- Bsep efflux inhibition with Taurocholate as probe substrate
- Direct efflux measurements
- Induction experiments - under development
- MRP2 efflux inhibition with Estradiol-17-beta-glucuronide as probe substrate- under development
- MRP2 efflux inhibition with Bilirubin glucuronide as probe substrate
- BSEP efflux inhibition with Taurocholate as probe substrate - under development
- Direct efflux measurements
- Induction experiments- under development
- Introductory bundling:
10% of the total cost ordered in the first three months will be credited against any MRP2, BCRP, BSEP products. - Cross promotional package:
20% of the total cost ordered in the first month will be credited against one transporter screening project, which is signed within six months.
b-clear@solvo.com.
With our best regards,
SOLVO Biotechnology
Business Development Team
CONTACT INFORMATION:
SOLVO Biotechnology
2 Gyár St. H-2040 Budaörs, HUNGARY
E-mail: sales@solvo.com
web: www.solvo.com
Phone: +36-23/503-940
Fax: +36-23/503-941
| Privileged/confidential information may be contained in this message. This communication is confidential and intended solely for the addressee(s). Unauthorized distribution, modification or disclosure of the contents may be unlawful. If you receive this in error, please notify the sender and delete it from your system. If you are not the addressee indicated in this message (or responsible for delivery of the message to such person), you may not copy or deliver this message to anyone. |
If you wish to
unsubscribe, please send a letter to 
with 'unsubscribe' in the subject field. |